



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 1919

SERIAL NUMBER 09/872,127	FILING DATE 06/01/2001 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. 5776.204-US
APPLICANTS Anker Jon Hansen, Charlottenlund, DENMARK; Tine Krogh Jorgensen, Olstykke, DENMARK; Uffe Bang Olsen, Vallengbaek, DENMARK;				
** CONTINUING DATA ***** THIS APPLICATION IS A CON OF PCT/DK99/00671 12/01/1999 AND CLAIMS BENEFIT OF 60/111,445 12/08/1998				
** FOREIGN APPLICATIONS ***** DENMARK PA 1998 01586 12/02/1998				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 08/29/2001				
Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Examiner's Signature _____ Initials _____	STATE OR COUNTRY DENMARK	SHEETS DRAWING	TOTAL CLAIMS 34 INDEPENDENT CLAIMS 1
ADDRESS Reza Green, Esq. Novo Nordisk of North America, Inc. Suite 6400 405 Lexington Avenue New York, NY 10174-6401				
TITLE Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis				
FILING FEE RECEIVED 1092	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	